机构：[1]Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.临床科室耳鼻咽喉-头颈外科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[2]Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases, Beijing Key Laboratory of Nasal Diseases, Key Laboratory of Otolaryngology Head and Neck Surgery, Ministry of Education, Capital Medical University, Beijing, China.研究所耳鼻咽喉科研究所首都医科大学附属北京同仁医院首都医科大学附属同仁医院[3]Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.[4]Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.临床科室变态反应科首都医科大学附属北京同仁医院首都医科大学附属同仁医院
Chronic rhinosinusitis with nasal polyps (CRSwNP), especially CRSwNP with type 2 inflammation, remains the most difficult-to-treat subtype with high prevalence worldwide. The emergence of biologics has the potential to fulfill the unmet medical needs of patients with CRSwNP driven by type 2 inflammation.A current review of the literature was performed to overview current and emerging biological therapies in the treatment of CRSwNP.In an era of precision medicine, biologics have been given expectations to provide customized therapies to patients with CRSwNP, particularly those with refractory CRSwNP. Large clinical trials and real-world experiences are both essential for the application of biologics. Moreover, to make biological therapy more tailored to patients, an in-depth understanding of the different mechanisms of biologics, further elucidating the relationship between biologics and conventional medical and surgical treatments, and identifying predictive biomarkers warrant thorough investigations.
基金：
This work was supported by grants from the national key R&D program of China (2022YFC2504100); National Natural Science Foundation of China (81900917, 82171108, 82025010, and 81870698); Changjiang Scholars and Innovative Research Team (IRT13082); CAMS Innovation Fund for Medical Sciences (2019-I2M-5-022); Beijing Municipal Science and Technology Project (Z181100001618002 and Z211100002921057); Capital’s Funds for Health Improvement and Research (CFH2022-1-1091); Beijing Municipal Administration of Hospitals’ Mission Plan (SML20150203); Beijing Municipal Administration of Hospitals’ Dengfeng plan (DFL20190202), and Dongcheng District Outstanding Talent Nurturing Program (2022-dchrcpyzz-3).
第一作者机构：[1]Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.[2]Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases, Beijing Key Laboratory of Nasal Diseases, Key Laboratory of Otolaryngology Head and Neck Surgery, Ministry of Education, Capital Medical University, Beijing, China.[3]Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.[2]Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases, Beijing Key Laboratory of Nasal Diseases, Key Laboratory of Otolaryngology Head and Neck Surgery, Ministry of Education, Capital Medical University, Beijing, China.[3]Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.[4]Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.[*1]Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, No. 1, Dongjiaominxiang, Dongcheng District, Beijing 100730, PR China[*2]Beijing Institute of Otolaryngology, No. 17, HouGouHuTong, DongCheng District, Beijing 100005, P.R. China
推荐引用方式(GB/T 7714)：
Jin Zeyi,Yan Bing,Zhang Luo,et al.Current and emerging biological therapies for Chronic rhinosinusitis with nasal polyps with type 2 inflammation[J].EXPERT OPINION ON INVESTIGATIONAL DRUGS.2023,32(10):909-919.doi:10.1080/13543784.2023.2273502.
APA：
Jin Zeyi,Yan Bing,Zhang Luo&Wang Chengshuo.(2023).Current and emerging biological therapies for Chronic rhinosinusitis with nasal polyps with type 2 inflammation.EXPERT OPINION ON INVESTIGATIONAL DRUGS,32,(10)
MLA：
Jin Zeyi,et al."Current and emerging biological therapies for Chronic rhinosinusitis with nasal polyps with type 2 inflammation".EXPERT OPINION ON INVESTIGATIONAL DRUGS 32..10(2023):909-919
：